Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals five molecular subgroups in young breast cancer (YBC) through proteogenomic analysis. Findings enhance HER2 assessment, offer new homologous recombination deficiency (HRD) tests, and predict recurrence in YBC patients.
Area Of Science
- Oncology
- Genomics
- Proteomics
Background
- Early-onset breast cancer (EBC) presents aggressive traits and is prevalent in East Asia, yet its molecular underpinnings remain incompletely understood.
- Young breast cancer (YBC), defined as age ≤40 years, requires distinct understanding due to its aggressive nature.
Purpose Of The Study
- To perform an integrated proteogenomic analysis on treatment-naïve primary tumor tissues from Korean YBC patients.
- To identify novel molecular subgroups and biomarkers for improved YBC patient stratification and treatment strategies.
Main Methods
- Proteogenomic analysis integrating genomic, transcriptomic, and proteomic data from 126 YBC patients.
- Development of a proteome-based homologous recombination deficiency (HRD) assay.
- Correlation analysis of protein-RNA expression to predict late recurrence.
Main Results
- Identification of five distinct functional subgroups within YBC, correlating with clinical characteristics and biological behavior.
- Enhanced proteogenomic assessment of HER2 status, improving its clinical significance.
- A novel proteome-based HRD analysis potentially overcoming limitations of genomic tests.
- Discovery of protein-RNA correlations for predicting late recurrence in hormone receptor-positive breast cancer.
- Development of a recurrence predictive index for luminal YBC subtypes.
Conclusions
- Proteogenomic analysis provides a deeper understanding of YBC molecular heterogeneity.
- Findings facilitate improved patient stratification, HER2 assessment, and identification of patients for targeted HR deficiency therapies.
- The study offers tools for predicting late recurrence and optimizing adjuvant treatment duration in YBC, leading to better clinical outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...